secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2024-11-25T23:59:59+00:00
Accession:  0001171843-24-006545
Event type: other_material
Sentiment:  negative
Materiality: 1.00
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cassava Sciences simufilam Phase 3 Alzheimer's trial misses all endpoints; studies halted
--------------------------------------------------------------------------------

- Simufilam failed to meet co-primary endpoints: ADAS-COG12 delta -0.39 (p=0.43), ADCS-ADL delta 0.51 (p=0.40).
- Company discontinues Phase 3 ReFocus-ALZ and open-label extension studies due to failed ReThink-ALZ results.
- Simufilam showed favorable safety profile; serious AEs 13.0% vs 9.0% placebo; 1 death vs 3 in placebo.
- Cash and equivalents approx $149M as of Q3 2024; company to evaluate next steps and present data at medical meeting.
- Patient demographics balanced; mild-to-moderate AD enrollment; placebo decline less pronounced than expected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000117184324006545/0001171843-24-006545-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000117184324006545/f8k_112524.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-006545

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer